NuVasive Stock Price, News & Analysis (NASDAQ:NUVA)

$47.86 +0.88 (+1.87 %)
(As of 02/25/2018 04:00 PM ET)
Previous Close$47.86
Today's Range$46.72 - $47.99
52-Week Range$44.62 - $81.68
Volume477,685 shs
Average Volume881,786 shs
Market Capitalization$2.44 billion
P/E Ratio40.22
Dividend YieldN/A
Beta0.5

About NuVasive (NASDAQ:NUVA)

NuVasive logoNuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. Its principal product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The platform includes its software-driven nerve detection and avoidance systems, including NVM5, and intraoperative monitoring services and support; MaXcess, an integrated split-blade retractor system, and a range of implants and biologics. The platform combines three product categories: its MaXcess retractors, specialized implants and fixation products, and nerve monitoring systems and service offerings that collectively enable surgeons to detect and navigate around nerves, while directing customized access to the spine for implant delivery.

Receive NUVA News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical Equipment, Supplies & Distribution
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:NUVA
CUSIP67070410
Phone858-909-1800

Debt

Debt-to-Equity Ratio0.76%
Current Ratio2.85%
Quick Ratio1.51%

Price-To-Earnings

Trailing P/E Ratio40.218487394958
Forward P/E Ratio25.06
P/E Growth1.34

Sales & Book Value

Annual Sales$962.07 million
Price / Sales2.54
Cash Flow$4.21 per share
Price / Cash11.37
Book Value$13.91 per share
Price / Book3.44

Profitability

Trailing EPS$1.19
Net Income$37.14 million
Net Margins6.36%
Return on Equity13.65%
Return on Assets6.17%

Miscellaneous

Employees2,200
Outstanding Shares50,970,000

NuVasive (NASDAQ:NUVA) Frequently Asked Questions

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How will NuVasive's stock buyback program work?

NuVasive announced that its board has approved a share repurchase plan on Wednesday, October 25th 2017, which allows the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company's board believes its stock is undervalued.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Tuesday, October, 24th. The medical device company reported $0.52 earnings per share for the quarter, topping analysts' consensus estimates of $0.48 by $0.04. The medical device company had revenue of $247.40 million for the quarter, compared to analyst estimates of $255.70 million. NuVasive had a return on equity of 13.65% and a net margin of 6.36%. NuVasive's quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.40 earnings per share. View NuVasive's Earnings History.

When will NuVasive make its next earnings announcement?

NuVasive is scheduled to release their next quarterly earnings announcement on Monday, February, 26th 2018. View Earnings Estimates for NuVasive.

Where is NuVasive's stock going? Where will NuVasive's stock price be in 2018?

15 equities research analysts have issued 1-year target prices for NuVasive's shares. Their predictions range from $60.00 to $90.00. On average, they anticipate NuVasive's share price to reach $71.64 in the next twelve months. View Analyst Ratings for NuVasive.

What are Wall Street analysts saying about NuVasive stock?

Here are some recent quotes from research analysts about NuVasive stock:

  • 1. According to Zacks Investment Research, "NuVasive's recent quarterly performances were promising significantly driven by solid international growth. The last-reported third quarter marked the fourth consecutive one registering more than 20% growth in international business. However, overall sales in the quarter were impacted by procedural volume-related challenges in the United States and the adverse impact of hurricanes Harvey and Irma on NuVasive’s U.S. results and Maria on the international front. With chances of fourth-quarter revenues being affected by Maria in Puerto Rico and with the anticipated lower U.S. procedural volumes to continue, NuVasive is pressed to reduce its full-year guidance, which is disappointing. Also, the contraction in gross margin is a matter of concern. Overall, for the past six months, NuVasive has been trading below the broader industry." (2/20/2018)
  • 2. Needham & Company LLC analysts commented, "We are upgrading NUVA to Buy from Underperform since: 1) we believe that consensus revenue and EPS estimates have declined to levels that are more realistic and likely conservative, 2) NUVA has done several acquisitions that probably aren’t fully factored into consensus revenue or EPS estimates (Vertera and SafePassage, which we estimate could add ~2% to NUVA’s 2018 revenue), 3) NUVA should see a significant benefit from tax reform (which we expect to increase its EPS by ~15% in 2018), and 4) we think NUVA shares are attractively valued considering the expected benefit from tax reform. We have raised our revenue and EPS estimates to reflect recent deals and tax reform." (1/4/2018)
  • 3. Canaccord Genuity analysts commented, "We note leading indicators of forward growth — new product flow (Less-ray, cervical iGA, Unite, pediatric deformity, expandable cages) and sales rep additions (+15 percent Y/Y in 2016) — should drive incremental growth opportunities entering the H2/16," the analyst said.On Track to Deliver Meaningful LeverageCanaccord Genuity believes the company is on track to deliver meaningful leverage over the next five years, although it expects M&A and continued investments to offset near-term improvements in operating margins."In sum, we continue to view the margin story positively but expect 2017 to be back-end loaded as NUVA realizes the benefits of sales force investments (building out peds team) and marketing efforts in Japan," the firm said.Guidance Reflects Changing SeasonalityThe firm noted that the company guided full-year revenues to $1.065 million, including a $10 million forex headwind, adjusted operating margins of 17.1 percent, up 100 basis points year-over-year, and earnings of $2 per share. However, the second quarter revenue guidance of $262 million was about $5 million below the consensus estimate, the firm added.According to the firm, this reflects the changing seasonality of the revenue cadence post the Ellipse Biotronic acquisitions. Concluding, the firm said, "We continue to believe that NuVasive is in prime share-taking position in the global spine market, driven by innovative new product flow, robust sales force additions, and broader tailwinds such as vendor consolidation."Furthermore, the margin expansion story remains intact and we see upside bias to estimates despite the second-half weighted guidance." (4/26/2017)

Who are some of NuVasive's key competitors?

Who are NuVasive's key executives?

NuVasive's management team includes the folowing people:

  • Gregory T. Lucier, Chairman of the Board, Chief Executive Officer (Age 53)
  • Rajesh J Asarpota, Chief Financial Officer, Executive Vice President (Age 50)
  • Joan B. Stafslien, Executive Vice President, General Counsel, Corporate Secretary (Age 52)
  • Carol A. Cox, Executive Vice President - External Affairs and Corporate Marketing (Age 52)
  • Peter Michael Leddy Ph.D., Executive Vice President, Global Human Resources, Integrations, Real Estate and Internal Communications (Age 53)
  • Matthew W. Link, Executive Vice President - Strategy, Technology and Corporate Development (Age 42)
  • Stephen Rozow, - Global Process Transformation (Age 48)
  • Vickie L. Capps, Independent Director (Age 55)
  • John A. DeFord Ph.D., Independent Director (Age 56)
  • Peter C. Farrell Ph.D., Independent Director (Age 75)

Who owns NuVasive stock?

NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Champlain Investment Partners LLC (5.62%), Viking Global Investors LP (3.51%), Fisher Asset Management LLC (2.53%), Eagle Asset Management Inc. (2.23%), OppenheimerFunds Inc. (2.07%) and TIAA CREF Investment Management LLC (1.65%). Company insiders that own NuVasive stock include Gregory T Lucier, Jason Hannon, Joan Stafslien, Lesley H Howe, Matthew Link, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Institutional Ownership Trends for NuVasive.

Who sold NuVasive stock? Who is selling NuVasive stock?

NuVasive's stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP, TIAA CREF Investment Management LLC, Guggenheim Capital LLC, OppenheimerFunds Inc., Teachers Advisors LLC, Metropolitan Life Insurance Co. NY, Tekla Capital Management LLC and Engineers Gate Manager LP. Company insiders that have sold NuVasive company stock in the last year include Jason Hannon and Lesley H Howe. View Insider Buying and Selling for NuVasive.

Who bought NuVasive stock? Who is buying NuVasive stock?

NuVasive's stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., Consonance Capital Management LP, State of Tennessee Treasury Department, AXA, Macquarie Group Ltd., Victory Capital Management Inc., Rice Hall James & Associates LLC and Champlain Investment Partners LLC. Company insiders that have bought NuVasive stock in the last two years include Gregory T Lucier, Joan Stafslien, Michael D Ohalleran, Patrick Miles and Peter Michael Leddy. View Insider Buying and Selling for NuVasive.

How do I buy NuVasive stock?

Shares of NuVasive can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is NuVasive's stock price today?

One share of NuVasive stock can currently be purchased for approximately $47.86.

How big of a company is NuVasive?

NuVasive has a market capitalization of $2.44 billion and generates $962.07 million in revenue each year. The medical device company earns $37.14 million in net income (profit) each year or $1.19 on an earnings per share basis. NuVasive employs 2,200 workers across the globe.

How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected]


MarketBeat Community Rating for NuVasive (NUVA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  549 (Vote Outperform)
Underperform Votes:  437 (Vote Underperform)
Total Votes:  986
MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

NuVasive (NASDAQ:NUVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.732.802.752.67
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $71.64$71.64$71.64$81.10
Price Target Upside: 46.60% upside37.80% upside26.29% upside31.57% upside

NuVasive (NASDAQ:NUVA) Consensus Price Target History

Price Target History for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ:NUVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018Leerink SwannDowngradeOutperform -> Market PerformMediumView Rating Details
1/17/2018Wells Fargo & CoDowngradeOutperform -> Market Perform$65.00MediumView Rating Details
1/9/2018Piper Jaffray CompaniesReiterated RatingBuy$90.00HighView Rating Details
1/4/2018Needham & Company LLCUpgradeUnderperform -> Buy$71.00LowView Rating Details
12/14/2017BMO Capital MarketsReiterated RatingBuy$70.00MediumView Rating Details
12/13/2017BTIG ResearchSet Price TargetBuy$74.00LowView Rating Details
11/10/2017Royal Bank of CanadaLower Price TargetOutperform -> Outperform$75.00 -> $70.00N/AView Rating Details
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$78.00N/AView Rating Details
10/25/2017Canaccord GenuityReiterated RatingBuy$75.00 -> $70.00N/AView Rating Details
10/19/2017BarclaysLower Price TargetOverweight$80.00 -> $65.00N/AView Rating Details
10/12/2017Robert W. BairdSet Price TargetHold$72.00 -> $60.00N/AView Rating Details
10/12/2017CowenSet Price TargetBuy$72.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$81.00 -> $70.00N/AView Rating Details
10/3/2017Jefferies GroupReiterated RatingBuy$79.00LowView Rating Details
9/21/2017GabelliReiterated RatingBuyLowView Rating Details
11/30/2016AegisInitiated CoverageBuy$72.00N/AView Rating Details
7/27/2016Brean CapitalBoost Price TargetBuy$60.00 -> $70.00N/AView Rating Details
(Data available from 2/25/2016 forward)

Earnings

NuVasive (NASDAQ:NUVA) Earnings History and Estimates Chart

Earnings by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.56N/AView Earnings Details
10/24/2017Q3 2017$0.48$0.52$255.70 million$247.40 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.44$0.46$261.95 million$260.60 millionViewN/AView Earnings Details
4/25/2017Q1 2017$0.37$0.38$250.52 million$249.86 millionViewN/AView Earnings Details
2/9/2017Q416$0.51$0.53$261.25 million$271.10 millionViewListenView Earnings Details
10/25/2016Q316$0.40$0.40$243.49 million$239.60 millionViewListenView Earnings Details
7/26/2016Q216$0.36$0.40$232.86 million$236.50 millionViewListenView Earnings Details
4/26/2016Q116$0.27$0.31$205.54 million$215.10 millionViewListenView Earnings Details
2/11/2016Q415$0.31$0.35$215.08 million$215.30 millionViewListenView Earnings Details
10/27/2015Q315$0.27$0.35$200.21 million$200.50 millionViewListenView Earnings Details
7/28/2015Q215$0.25$0.31$200.71 million$202.91 millionViewListenView Earnings Details
5/4/2015Q115$0.21$0.30$189.30 million$192.40 millionViewListenView Earnings Details
2/24/2015Q4$0.37$0.39$201.40 million$204.30 millionViewListenView Earnings Details
10/30/2014Q314$0.14$0.09$179.30 million$189.90 millionViewListenView Earnings Details
7/29/2014Q214$0.25$0.28$177.50 million$190.70 millionViewListenView Earnings Details
4/29/2014Q114$0.13$0.29$171.30 million$177.50 millionViewListenView Earnings Details
3/3/2014Q413$0.32$0.37$181.24 million$190.80 millionViewListenView Earnings Details
10/29/2013Q313$0.24$0.39$158.30 million$169.20 millionViewListenView Earnings Details
7/30/2013Q2 2013$0.23$0.20$161.67 million$165.70 millionViewListenView Earnings Details
4/30/2013Q1 2013$0.22$0.26$157.34 million$159.50 millionViewListenView Earnings Details
2/26/2013Q4 2012$0.21$0.34$156.35 million$165.80 millionViewListenView Earnings Details
10/24/2012$0.21$0.23ViewN/AView Earnings Details
7/25/2012$0.23$0.27ViewN/AView Earnings Details
4/30/2012$0.18$0.20ViewN/AView Earnings Details
2/22/2012$0.22$0.27ViewN/AView Earnings Details
10/27/2011$0.24$0.26ViewN/AView Earnings Details
7/25/2011$0.28$0.30ViewN/AView Earnings Details
5/5/2011$0.19$0.24ViewN/AView Earnings Details
2/23/2011$0.42$0.46ViewN/AView Earnings Details
10/28/2010Q3 2010$0.26$0.29ViewN/AView Earnings Details
7/27/2010Q2 2010$0.18$0.24ViewN/AView Earnings Details
4/20/2010Q1 2010$0.07$0.09ViewN/AView Earnings Details
2/25/2010Q4 2009$0.11$0.11ViewN/AView Earnings Details
10/20/2009Q3 2009$0.05$0.15ViewN/AView Earnings Details
7/23/2009Q2 2009($0.02)$0.07ViewN/AView Earnings Details
4/22/2009Q1 2009($0.20)($0.02)ViewN/AView Earnings Details
2/25/2009Q4 2008$0.12$0.16ViewN/AView Earnings Details
10/22/2008Q3 2008$0.01$0.04ViewN/AView Earnings Details
7/24/2008Q2 2008($0.03)($0.01)ViewN/AView Earnings Details
4/22/2008Q1 2008($0.10)($0.10)ViewN/AView Earnings Details
2/19/2008Q4 2007($0.04)($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

NuVasive (NASDAQ:NUVA) Earnings Estimates

2018 EPS Consensus Estimate: $2.31
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.38$0.51$0.44
Q2 20183$0.56$0.60$0.58
Q3 20183$0.57$0.72$0.62
Q4 20183$0.63$0.71$0.66
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for NuVasive (NASDAQ:NUVA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

NuVasive (NASDAQ NUVA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for NuVasive (NASDAQ:NUVA)
Institutional Ownership by Quarter for NuVasive (NASDAQ:NUVA)

NuVasive (NASDAQ NUVA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/29/2017Gregory T LucierCEOBuy2,000$61.52$123,040.00View SEC Filing  
8/18/2017Lesley H. HoweDirectorSell3,970$64.64$256,620.80View SEC Filing  
8/17/2017Gregory T LucierCEOBuy5,000$66.22$331,100.00View SEC Filing  
8/1/2017Peter Michael LeddyEVPBuy7,850$63.88$501,458.00View SEC Filing  
3/8/2017Jason HannonInsiderSell24,840$74.22$1,843,624.80View SEC Filing  
2/14/2017Lesley H. HoweDirectorSell6,049$73.26$443,149.74View SEC Filing  
12/12/2016Matthew LinkInsiderSell10,303$67.99$700,500.97View SEC Filing  
11/4/2016Michael D OhalleranDirectorBuy4,200$58.26$244,692.00View SEC Filing  
11/2/2016Patrick MilesDirectorBuy16,967$58.97$1,000,543.99View SEC Filing  
11/1/2016Patrick MilesDirectorBuy16,667$59.00$983,353.00View SEC Filing  
10/31/2016Joan StafslienEVPBuy5,000$59.68$298,400.00View SEC Filing  
10/31/2016Michael D OhalleranDirectorBuy4,205$59.47$250,071.35View SEC Filing  
8/23/2016Jason HannonEVPSell2,625$64.80$170,100.00View SEC Filing  
8/2/2016Jason HannonEVPSell11,184$62.70$701,236.80View SEC Filing  
8/2/2016Lesley H. HoweDirectorSell3,602$62.44$224,908.88View SEC Filing  
7/20/2016Jason HannonEVPSell2,920$62.80$183,376.00View SEC Filing  
6/16/2016Jason HannonEVPSell14,534$57.57$836,722.3837,616View SEC Filing  
1/6/2016Patrick MilesCOOSell10,723$54.03$579,363.6931,646View SEC Filing  
12/16/2015Patrick MilesCOOSell9,127$52.56$479,715.1231,646View SEC Filing  
12/7/2015Quentin S BlackfordCFOSell15,000$51.10$766,500.002,599View SEC Filing  
12/3/2015Patrick MilesCOOSell5,873$52.51$308,391.2340,773View SEC Filing  
11/2/2015Patrick MilesCOOSell15,000$48.12$721,800.0032,627View SEC Filing  
10/5/2015Matthew LinkinsiderSell1,714$50.72$86,934.0853,089View SEC Filing  
10/3/2015Quentin S BlackfordCFOSell5,000$36.30$181,500.00View SEC Filing  
10/1/2015Patrick MilesCOOSell15,000$48.10$721,500.0047,627View SEC Filing  
9/8/2015Russell PowersEVPSell5,806$51.64$299,821.8462,024View SEC Filing  
9/2/2015Jason HannonEVPSell11,962$52.02$622,263.2418,565View SEC Filing  
9/1/2015Patrick MilesCOOSell15,000$52.03$780,450.0062,627View SEC Filing  
8/31/2015Patrick MilesCOOSell15,000$53.34$800,100.0062,627View SEC Filing  
7/20/2015Jason HannonEVPSell15,000$49.60$744,000.00View SEC Filing  
6/15/2015Gregory T LucierCEOBuy4,491$49.49$222,259.59View SEC Filing  
6/12/2015Gregory T LucierCEOBuy8,000$50.10$400,800.00View SEC Filing  
6/10/2015Gregory T LucierCEOBuy10,000$49.10$491,000.00View SEC Filing  
6/8/2015Gregory T LucierCEOBuy10,000$49.26$492,600.00View SEC Filing  
6/4/2015Gregory T LucierCEOBuy10,000$49.71$497,100.00View SEC Filing  
6/2/2015Gregory T LucierCEOBuy8,000$49.96$399,680.00View SEC Filing  
6/2/2015Patrick MilesCOOSell4,194$49.47$207,477.18View SEC Filing  
5/29/2015Jack R BlairDirectorSell3,703$50.16$185,742.48View SEC Filing  
5/28/2015Gregory T LucierCEOBuy34,000$49.25$1,674,500.00View SEC Filing  
5/28/2015Russell PowersEVPSell8,042$49.00$394,058.00View SEC Filing  
5/19/2015Patrick MilesCOOSell15,000$47.52$712,800.00View SEC Filing  
5/1/2015Russell PowersEVPSell11,881$45.21$537,140.01View SEC Filing  
4/24/2015Russell PowersEVPSell3,888$44.07$171,344.16View SEC Filing  
3/13/2015Patrick MilesCOOSell7,920$45.52$360,518.40View SEC Filing  
3/9/2015Alexis V LukianovCEOSell5,313$44.82$238,128.66View SEC Filing  
3/3/2015Matthew LinkInsiderSell7,500$44.46$333,450.00View SEC Filing  
3/2/2015Jason HannonEVPSell5,085$45.06$229,130.10View SEC Filing  
2/9/2015Alexis V LukianovCEOSell5,454$46.10$251,429.40View SEC Filing  
2/5/2015Matthew LinkInsiderSell4,078$45.77$186,650.06View SEC Filing  
2/3/2015Patrick MilesCOOSell15,000$45.53$682,950.00View SEC Filing  
1/28/2015Keith ValentineCOOSell6,970$46.96$327,311.20View SEC Filing  
1/12/2015Alexis V LukianovCEOSell7,452$49.69$370,289.88View SEC Filing  
1/5/2015Jason HannonEVPSell12,117$46.82$567,317.94View SEC Filing  
1/5/2015Patrick MilesInsiderSell15,000$46.61$699,150.00View SEC Filing  
12/30/2014Jason HannonEVPSell15,000$47.63$714,450.00View SEC Filing  
12/29/2014Jason HannonEVPSell3,146$47.57$149,655.22View SEC Filing  
12/24/2014Patrick MilesInsiderSell15,000$47.52$712,800.00View SEC Filing  
12/19/2014Keith ValentineCOOSell5,893$47.78$281,567.54View SEC Filing  
12/1/2014Keith ValentineCOOSell2,500$43.66$109,150.00View SEC Filing  
11/19/2014Keith ValentineCOOSell5,582$43.32$241,812.24View SEC Filing  
11/19/2014Quentin S BlackfordCFOSell7,698$43.41$334,170.18View SEC Filing  
11/7/2014Alexis V LukianovCEOSell25,000$41.40$1,035,000.00View SEC Filing  
11/3/2014Keith ValentineCOOSell2,500$40.61$101,525.00View SEC Filing  
10/2/2014Keith ValentineCOOSell2,500$35.00$87,500.00View SEC Filing  
9/2/2014Keith ValentineCOOSell2,500$35.14$87,850.00View SEC Filing  
8/1/2014Keith ValentineCOOSell2,500$37.11$92,775.00View SEC Filing  
8/1/2014Michael LambertCFOSell4,010$37.11$148,811.10View SEC Filing  
7/30/2014Jason HannonEVPSell5,000$39.00$195,000.00View SEC Filing  
7/10/2014Russell PowersEVPSell3,200$33.43$106,976.00View SEC Filing  
7/1/2014Keith ValentineCOOSell2,500$35.65$89,125.00View SEC Filing  
7/1/2014Michael LambertCFOSell23,225$35.48$824,023.00View SEC Filing  
6/20/2014Keith ValentineCOOSell5,000$35.00$175,000.00View SEC Filing  
6/20/2014Russell PowersEVPSell9,526$35.00$333,410.00View SEC Filing  
5/5/2014Robert HuntDirectorSell20,000$34.25$685,000.0034,500View SEC Filing  
5/2/2014Michael LambertCFOSell13,096$33.07$433,084.7251,695View SEC Filing  
4/1/2014Keith ValentineCOOSell2,500$38.41$96,025.0088,985View SEC Filing  
3/11/2014Peter FarrellDirectorSell48,000$36.88$1,770,240.006,794View SEC Filing  
1/21/2014Jason HannonEVPSell10,095$36.60$369,477.008,899View SEC Filing  
1/16/2014Keith ValentineCOOSell20,000$37.96$759,200.0044,226View SEC Filing  
1/7/2014Alexis LukianovCEOSell34,217$34.29$1,173,300.9355,740View SEC Filing  
1/7/2014Craig HunsakerSVPSell4,980$35.00$174,300.0021,142View SEC Filing  
12/30/2013Craig HunsakerSVPSell4,275$32.10$137,227.5024,980View SEC Filing  
12/23/2013Michael LambertCFOSell17,091$32.49$555,286.5913,096View SEC Filing  
11/7/2013Alexis LukianovCEOSell5,000$31.45$157,250.0072,827View SEC Filing  
10/30/2013Jason HannonEVPSell2,334$28.90$67,452.60View SEC Filing  
10/30/2013Patrick MilesInsiderSell21,223$31.10$660,035.30View SEC Filing  
10/28/2013Patrick MilesInsiderSell7,331$25.72$188,553.32View SEC Filing  
10/21/2013Russell PowersVPSell12,500$25.39$317,375.00View SEC Filing  
10/11/2013Jason HannonEVPSell1,000$26.00$26,000.0019,991View SEC Filing  
10/7/2013Jason HannonEVPSell8,705$23.99$208,832.9519,991View SEC Filing  
10/7/2013Michael LambertCFOSell15,442$24.04$371,225.6830,187View SEC Filing  
8/6/2013Richard Treharne IIIDirectorBuy2,000$23.26$46,520.00View SEC Filing  
7/12/2013Craig E HunsakerSVPSell2,000$27.00$54,000.00View SEC Filing  
7/8/2013Alexis V LukianovCEOSell5,000$25.74$128,700.00View SEC Filing  
7/1/2013Keith ValentineCOOSell1,698$25.00$42,450.00View SEC Filing  
5/13/2013Alexis V LukianovCEOSell7,500$22.71$170,325.00View SEC Filing  
5/8/2013Peter Michael LeddyDirectorBuy2,400$22.24$53,376.00View SEC Filing  
5/7/2013Alexis V LukianovCEOSell12,500$22.11$276,375.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

NuVasive (NASDAQ NUVA) News Headlines

Source:
DateHeadline
Financial Survey: Neurometrix (NURO) vs. NuVasive (NUVA)Financial Survey: Neurometrix (NURO) vs. NuVasive (NUVA)
www.americanbankingnews.com - February 25 at 11:58 AM
NuVasive, Inc. (NUVA) Shares Sold by Sei Investments Co.NuVasive, Inc. (NUVA) Shares Sold by Sei Investments Co.
www.americanbankingnews.com - February 25 at 7:48 AM
$272.29 Million in Sales Expected for NuVasive, Inc. (NUVA) This Quarter$272.29 Million in Sales Expected for NuVasive, Inc. (NUVA) This Quarter
www.americanbankingnews.com - February 25 at 2:02 AM
365,000 Shares in NuVasive, Inc. (NUVA) Acquired by State of Tennessee Treasury Department365,000 Shares in NuVasive, Inc. (NUVA) Acquired by State of Tennessee Treasury Department
www.americanbankingnews.com - February 24 at 2:34 PM
Schwab Charles Investment Management Inc. Acquires 20,686 Shares of NuVasive, Inc. (NUVA)Schwab Charles Investment Management Inc. Acquires 20,686 Shares of NuVasive, Inc. (NUVA)
www.americanbankingnews.com - February 24 at 4:38 AM
 Brokerages Expect NuVasive, Inc. (NUVA) Will Post Earnings of $0.56 Per Share Brokerages Expect NuVasive, Inc. (NUVA) Will Post Earnings of $0.56 Per Share
www.americanbankingnews.com - February 23 at 11:12 PM
NuVasives SpineTRACK Registry Gains New CMS DesignationNuVasive's SpineTRACK Registry Gains New CMS Designation
www.msn.com - February 21 at 4:58 PM
NuVasive's SpineTRACK Registry Gains New CMS DesignationNuVasive's SpineTRACK Registry Gains New CMS Designation
finance.yahoo.com - February 21 at 4:58 PM
NuVasive SpineTRACK Registry Named Qualified Clinical Data Registry By Centers Of Medicare And Medicaid ServicesNuVasive SpineTRACK Registry Named Qualified Clinical Data Registry By Centers Of Medicare And Medicaid Services
finance.yahoo.com - February 20 at 5:13 PM
NuVasive (NUVA) Stock Rating Lowered by Zacks Investment ResearchNuVasive (NUVA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - February 20 at 3:06 PM
Zacks Investment Research Upgrades NuVasive (NUVA) to BuyZacks Investment Research Upgrades NuVasive (NUVA) to Buy
www.americanbankingnews.com - February 19 at 1:24 PM
NuVasive (NUVA) to Release Earnings on MondayNuVasive (NUVA) to Release Earnings on Monday
www.americanbankingnews.com - February 19 at 6:36 AM
BRIEF-John DeFord To Join NuVasive Board Of DirectorsBRIEF-John DeFord To Join NuVasive Board Of Directors
www.reuters.com - February 9 at 9:29 AM
NuVasive (NUVA) Appoints John DeFord to BoardNuVasive (NUVA) Appoints John DeFord to Board
www.streetinsider.com - February 9 at 9:29 AM
Nevro (NVRO) & NuVasive (NUVA) Head to Head SurveyNevro (NVRO) & NuVasive (NUVA) Head to Head Survey
www.americanbankingnews.com - February 8 at 11:14 PM
John DeFord To Join NuVasive Board Of DirectorsJohn DeFord To Join NuVasive Board Of Directors
finance.yahoo.com - February 8 at 4:08 PM
Nuvasive Announces Conference Call And Webcast Of Fourth Quarter And Full Year 2017 ResultsNuvasive Announces Conference Call And Webcast Of Fourth Quarter And Full Year 2017 Results
finance.yahoo.com - February 8 at 8:39 AM
Zacks: Analysts Anticipate NuVasive, Inc. (NUVA) Will Post Quarterly Sales of $272.29 MillionZacks: Analysts Anticipate NuVasive, Inc. (NUVA) Will Post Quarterly Sales of $272.29 Million
www.americanbankingnews.com - February 8 at 2:26 AM
NuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.56 Per ShareNuVasive, Inc. (NUVA) Expected to Announce Earnings of $0.56 Per Share
www.americanbankingnews.com - February 6 at 11:22 PM
Q2 2018 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Leerink SwannQ2 2018 Earnings Estimate for NuVasive, Inc. (NUVA) Issued By Leerink Swann
www.americanbankingnews.com - February 5 at 3:16 AM
NuVasive, Inc. (NUVA) Given Consensus Recommendation of "Buy" by AnalystsNuVasive, Inc. (NUVA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 7:24 PM
NuVasive (NUVA) to Release Earnings on WednesdayNuVasive (NUVA) to Release Earnings on Wednesday
www.americanbankingnews.com - January 31 at 2:48 AM
Research Analysts Issue Forecasts for NuVasive, Inc.s Q1 2018 Earnings (NUVA)Research Analysts Issue Forecasts for NuVasive, Inc.'s Q1 2018 Earnings (NUVA)
www.americanbankingnews.com - January 22 at 3:52 AM
Zacks: Brokerages Anticipate NuVasive, Inc. (NUVA) to Announce $0.56 Earnings Per ShareZacks: Brokerages Anticipate NuVasive, Inc. (NUVA) to Announce $0.56 Earnings Per Share
www.americanbankingnews.com - January 21 at 1:14 AM
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Accuray, K2M Group, NuVasive, and NovoCureQuotidian Technical Highlights on Selected Medical Equipment Stocks -- Accuray, K2M Group, NuVasive, and NovoCure
www.bizjournals.com - January 18 at 11:16 AM
Nuvasive Enters Oversold Territory (NUVA)Nuvasive Enters Oversold Territory (NUVA)
www.nasdaq.com - January 17 at 4:38 PM
NuVasive (NUVA) Rating Lowered to Strong Sell at BidaskClubNuVasive (NUVA) Rating Lowered to Strong Sell at BidaskClub
www.americanbankingnews.com - January 14 at 10:30 PM
Global Spine Market 2017-2021 with Focus on Spinal Fusion: Industry Analysis & Outlook - Rising Cases of Spinal Cord Injury Driving the Market - Research and MarketsGlobal Spine Market 2017-2021 with Focus on Spinal Fusion: Industry Analysis & Outlook - Rising Cases of Spinal Cord Injury Driving the Market - Research and Markets
www.businesswire.com - January 10 at 4:36 PM
Intraoperative Neuromonitoring Market - Global Opportunity Analysis and Industry Forecast, 2014-2022Intraoperative Neuromonitoring Market - Global Opportunity Analysis and Industry Forecast, 2014-2022
www.prnewswire.com - January 10 at 4:36 PM
NuVasive Q4 Preliminary Results Fail to Cheer InvestorsNuVasive Q4 Preliminary Results Fail to Cheer Investors
finance.yahoo.com - January 10 at 10:24 AM
NuVasive (NUVA) Rating Reiterated by Piper Jaffray CompaniesNuVasive (NUVA) Rating Reiterated by Piper Jaffray Companies
www.americanbankingnews.com - January 9 at 1:38 PM
Celgene, Dave& Busters slide while Kohls and Crocs riseCelgene, Dave& Buster's slide while Kohl's and Crocs rise
www.latimes.com - January 9 at 10:13 AM
NuVasive, Inc. (NUVA) Given Average Recommendation of "Buy" by BrokeragesNuVasive, Inc. (NUVA) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 8 at 10:02 PM
Here's What Pressured NuVasive, Inc. Stock TodayHere's What Pressured NuVasive, Inc. Stock Today
finance.yahoo.com - January 8 at 4:42 PM
Heres What Pressured NuVasive, Inc. Stock TodayHere's What Pressured NuVasive, Inc. Stock Today
www.fool.com - January 8 at 2:37 PM
NuVasive Sees FY17 Revenue In Line With Prior Guidance - Quick FactsNuVasive Sees FY17 Revenue In Line With Prior Guidance - Quick Facts
www.nasdaq.com - January 8 at 10:30 AM
NuVasive Announces Preliminary Unaudited Full Year 2017 Revenue Results And Preliminary 2018 OutlookNuVasive Announces Preliminary Unaudited Full Year 2017 Revenue Results And Preliminary 2018 Outlook
finance.yahoo.com - January 8 at 10:30 AM
Integra Lifesciences (IART) versus NuVasive (NUVA) Critical ContrastIntegra Lifesciences (IART) versus NuVasive (NUVA) Critical Contrast
www.americanbankingnews.com - January 6 at 11:36 PM
Stocks To Watch: CES Headlines Blockbuster Conference SlateStocks To Watch: CES Headlines Blockbuster Conference Slate
www.nasdaq.com - January 6 at 10:16 AM
NuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $272.74 MillionNuVasive, Inc. (NUVA) Expected to Post Quarterly Sales of $272.74 Million
www.americanbankingnews.com - January 6 at 6:32 AM
NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF Procedures - PR Newswire (press release)NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF Procedures - PR Newswire (press release)
www.prnewswire.com - January 4 at 4:37 PM
NuVasive To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)NuVasive To Present At The 36th Annual JP Morgan Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - January 4 at 4:37 PM
Medtech Player Bounds On Upgrade Amid Tax Reform, AcquisitionsMedtech Player Bounds On Upgrade Amid Tax Reform, Acquisitions
finance.yahoo.com - January 4 at 4:37 PM
NuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF ProceduresNuVasive Extends First-Of-Its-Kind Porous PEEK Interbody To TLIF And PLIF Procedures
finance.yahoo.com - January 4 at 10:14 AM
$0.56 Earnings Per Share Expected for NuVasive, Inc. (NUVA) This Quarter$0.56 Earnings Per Share Expected for NuVasive, Inc. (NUVA) This Quarter
www.americanbankingnews.com - January 4 at 5:10 AM
NuVasive To Present At The 36th Annual J.P. Morgan Healthcare ConferenceNuVasive To Present At The 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 4:40 PM
BidaskClub Downgrades NuVasive (NUVA) to SellBidaskClub Downgrades NuVasive (NUVA) to Sell
www.americanbankingnews.com - December 28 at 3:26 PM
ETFs with exposure to NuVasive, Inc. : December 28, 2017ETFs with exposure to NuVasive, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 12:53 PM
Comparing NuVasive (NUVA) and Sientra (SIEN)Comparing NuVasive (NUVA) and Sientra (SIEN)
www.americanbankingnews.com - December 24 at 3:30 PM
NuVasive Comments On Expected Impact Of US Tax Reform - PR Newswire (press release)NuVasive Comments On Expected Impact Of US Tax Reform - PR Newswire (press release)
www.prnewswire.com - December 23 at 12:33 AM

SEC Filings

NuVasive (NASDAQ:NUVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

NuVasive (NASDAQ:NUVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

NuVasive (NASDAQ NUVA) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.